Terns Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 90.21 million compared to USD 60.35 million a year ago. Basic loss per share from continuing operations was USD 1.27 compared to USD 1.67 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.37 USD | -7.41% | -0.27% | +13.56% |
May. 13 | Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 08 | Terns Pharmaceuticals, Inc. Announces Executive Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.56% | 477M | |
+34.01% | 51.07B | |
+33.84% | 38.86B | |
-8.02% | 38.78B | |
-8.98% | 26.69B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- TERN Stock
- News Terns Pharmaceuticals, Inc.
- Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023